image
Healthcare - Medical - Devices - NASDAQ - US
$ 7.76
3.47 %
$ 205 M
Market Cap
-3.25
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one RCEL stock under the worst case scenario is HIDDEN Compared to the current market price of 7.76 USD, AVITA Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one RCEL stock under the base case scenario is HIDDEN Compared to the current market price of 7.76 USD, AVITA Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one RCEL stock under the best case scenario is HIDDEN Compared to the current market price of 7.76 USD, AVITA Medical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RCEL

image
$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
50.6 M REVENUE
254.49%
-40.4 M OPERATING INCOME
5.33%
-39.2 M NET INCOME
6.81%
-28 M OPERATING CASH FLOW
-23.27%
-28.4 M INVESTING CASH FLOW
-3252.63%
1.32 M FINANCING CASH FLOW
-98.28%
21.2 M REVENUE
20.29%
-14.3 M OPERATING INCOME
14.39%
-13.6 M NET INCOME
13.07%
-14 M OPERATING CASH FLOW
-2.16%
33.9 M INVESTING CASH FLOW
22.78%
933 K FINANCING CASH FLOW
263.54%
Balance Sheet AVITA Medical, Inc.
image
Current Assets 128 M
Cash & Short-Term Investments 117 M
Receivables 5.19 M
Other Current Assets 6.73 M
Non-Current Assets 15.9 M
Long-Term Investments 10.2 M
PP&E 3.01 M
Other Non-Current Assets 2.68 M
80.74 %3.59 %4.67 %7.05 %Total Assets$144.3m
Current Liabilities 15.7 M
Accounts Payable 4.41 M
Short-Term Debt 612 K
Other Current Liabilities 10.7 M
Non-Current Liabilities 4.16 M
Long-Term Debt 449 K
Other Non-Current Liabilities 3.71 M
22.20 %3.08 %53.79 %18.67 %Total Liabilities$19.9m
EFFICIENCY
Earnings Waterfall AVITA Medical, Inc.
image
Revenue 50.6 M
Cost Of Revenue 8.87 M
Gross Profit 41.7 M
Operating Expenses 80.8 M
Operating Income -40.4 M
Other Expenses -1.23 M
Net Income -39.2 M
60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)51m(9m)42m(81m)(40m)1m(39m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
82.45% GROSS MARGIN
82.45%
-79.91% OPERATING MARGIN
-79.91%
-77.47% NET MARGIN
-77.47%
-31.47% ROE
-31.47%
-27.14% ROA
-27.14%
-31.30% ROIC
-31.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AVITA Medical, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)2013201320142014201520152016201620172017201820182019201920202020202120212022202220232023
Net Income -39.2 M
Depreciation & Amortization 834 K
Capital Expenditures -664 K
Stock-Based Compensation 10.3 M
Change in Working Capital -1.8 M
Others 1.14 M
Free Cash Flow -28.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AVITA Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for RCEL of $11.5 , with forecasts ranging from a low of $9 to a high of $14 .
RCEL Lowest Price Target Wall Street Target
9 USD 15.98%
RCEL Average Price Target Wall Street Target
11.5 USD 48.20%
RCEL Highest Price Target Wall Street Target
14 USD 80.41%
Price
Max Price Target
Min Price Target
Average Price Target
151514141313121211111010998877May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership AVITA Medical, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
212 K USD 2
0-3 MONTHS
18.5 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
8.9 K USD 1
9-12 MONTHS
7. News
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. globenewswire.com - 2 weeks ago
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm. globenewswire.com - 1 month ago
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference AVITA Medical announced that Jim Corbett, CEO, will present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. Eastern Time. globenewswire.com - 1 month ago
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
After Sales Rebound In January, AVITA Is Set Up For A Monster Year After Sales Rebound In January, AVITA Is Set Up For A Monster Year seekingalpha.com - 2 months ago
AVITA Medical to Host Investor Webinar Briefing AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT. globenewswire.com - 2 months ago
AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 months ago
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 2 months ago
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance. seekingalpha.com - 3 months ago
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini seekingalpha.com - 3 months ago
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024. benzinga.com - 3 months ago
Avita Medical price target lowered to $14 from $20 at Lake Street Lake Street analyst Brooks O'Neil lowered the firm's price target on Avita Medical to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 commercial revenue that was below the firm's estimate and consensus and management lowered the expected FY24 revenue outlook. The company also provided initial FY25 revenue guidance that was below the firm's previous revenue estimate, which Lake Street calls "disappointing." However, with shares off nearly 22% in the after hours, the firm is maintaining a Buy rating as it continues to think this is a significant year for Avita, the analyst added. https://thefly.com - 3 months ago
8. Profile Summary

AVITA Medical, Inc. RCEL

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 205 M
Dividend Yield 0.00%
Description AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Contact 28159 Avenue Stanford, Valencia, CA, 91355 https://www.avitamedical.com
IPO Date May 14, 2012
Employees 260
Officers David Melbye Senior Vice President of Operations Dr. Katie Bush Ph.D. Senior Vice President of Scientific & Medical Affairs Ms. Jessica Ekeberg Director of Investor Relations Mr. Rob Hall Senior Vice President of Human Resources Mr. David O'Toole Chief Financial Officer Ms. Debbie Garner Senior Vice President of Global Marketing & Strategy Dr. Niraj Doshi J.D., P.M.P., Ph.D. Senior Vice President of Product Development & Program Management Ms. Nicole Linda Kelsey Chief Legal & Compliance Officer and Corporate Secretary Mr. James M. Corbett Chief Executive Officer, President & Executive Director Mr. Ron Lagerquist Senior Vice President of Quality Assurance & Regulatory Affairs